

**Amendments to the Claims**

Following is a complete listing of the claims pending in the application, as amended:

1. (Original) A dosage form comprising
  - (a) a membrane defining a compartment, the membrane having an exit orifice formed or formable therein and at least a portion of the membrane being semipermeable;
  - (b) an expandable layer located within the compartment remote from the exit orifice and in fluid communication with the semipermeable portion of the membrane;
  - (c) a delay layer located adjacent the exit orifice;
  - (d) a drug layer located within the compartment between the delay layer and the expandable layer; and
  - (e) an interface boundary between the delay layer and the drug layer, the interface boundary being convex in shape relative to the exit orifice.
2. (Original) The dosage form of Claim 1 wherein the delay layer and the drug layer are formed by a compression sequence in which the delay layer is compressed into its form prior to the drug layer being compressed into its form.
3. (Original) The dosage form of Claim 1 wherein:

the delay layer exhibits a higher viscosity than the drug layer when both are subjected to the same level of hydration.
4. (Original) The dosage form of Claim 1 wherein:

the viscosity of the delay layer is higher than the viscosity of the drug layer at equivalent aqueous saturation levels.
- 5.-27. (Canceled)

28. (Currently amended) The dosage form of Claim 1 wherein the drug layer comprises a drug selected from the group of cyclobenzaprine, amitriptyline, imipramine and desipramine.

29. (Original) The dosage form of Claim 1 wherein the drug layer comprises cyclobenzaprine and that provides a cyclobenzaprine plasma concentration of 6 to 8 ng/ml three to four hours after dosing and approximately 8 to 12 ng/ml eighteen to twenty hours after oral administration in a human.

30.-39. (Canceled)